Ten years after the sequencing of the human genome, the use of epigenetics in developing targeted cancer treatments is growing rapidly. This panel will discuss recent discoveries in epigenetic abnormalities and what the implications are for cancer treatment, in addition to specific emerging therapies on the forefront of this new and cutting-edge research.
• Bruno Osterwalder, MD, Senior Vice President, Senior Strategic Advisor Oncology,
Global Drug Development and Medical, Merck Serono
• Jean-Pierre Armand, MD, Senior Consultant, Institut Goustave Roussy
• Bing Zhu, PhD, Associate Investigator, National Institute of Biological Sciences, Beijing, China